MaxCyte signs platform license agreement with Adicet Bio
MaxCyte’s Flow Electroporation technology and ExPERT platform to support the development of Adicet’s gamma delta T cell therapy gene edited programs
11 Aug 2025
MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics, has announced it has signed a strategic platform license (SPL) with Adicet Bio, Inc., a biotechnology company focused on the development of allogeneic gamma delta T cell therapies for cancer and autoimmune diseases.
Under the terms of the agreement, Adicet Bio will obtain non-exclusive research, clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform. In return, MaxCyte is entitled to receive platform licensing fees and program-related revenue.
Adicet Bio has developed a proprietary manufacturing process to activate and expand distinct subsets of gamma delta T cells, enabling scalable production of its off-the-shelf, allogeneic cell therapies for use on demand in the clinical setting. The company’s approach combines non-viral gene editing with a robust expansion platform to deliver potent cell therapy products with the potential to treat a broad range of cancers and autoimmune disorders.
“We are pleased to support Adicet Bio as they expand their allogeneic gamma delta T cell manufacturing capabilities to include non-viral gene editing delivery,” said Maher Masoud, President and Chief Executive Officer of MaxCyte. “This collaboration underscores the versatility of our platform and its ability to enable the development of next-generation cell therapy candidates with increased efficiency and accessibility.”
MaxCyte’s ExPERT™ instrument portfolio represents the next generation of clinically and commercially validated electroporation technology for complex and scalable cell engineering. By delivering high transfection efficiency and cell viability, seamless scalability and enhanced functionality, the ExPERT™ platform delivers the high-end performance essential to enabling the next wave of biological and cellular therapeutics.